Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by investment analysts at StockNews.com to a “sell” rating in a report released on Tuesday.

ARWR has been the topic of a number of other reports. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, October 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. B. Riley reaffirmed a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Finally, Piper Sandler reissued an “overweight” rating and issued a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, October 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Trading Down 2.1 %

NASDAQ ARWR traded down $0.46 during trading hours on Tuesday, reaching $21.51. The company’s stock had a trading volume of 845,165 shares, compared to its average volume of 1,199,756. The business has a 50-day simple moving average of $20.27 and a 200 day simple moving average of $23.48. The stock has a market cap of $2.67 billion, a PE ratio of -4.61 and a beta of 0.93. Arrowhead Pharmaceuticals has a 52 week low of $17.05 and a 52 week high of $39.83.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Arrowhead Pharmaceuticals by 16.2% in the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock worth $354,756,000 after acquiring an additional 1,731,974 shares during the period. Avoro Capital Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 3.9% in the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after buying an additional 333,333 shares during the last quarter. American International Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 13.4% during the 1st quarter. American International Group Inc. now owns 220,217 shares of the biotechnology company’s stock worth $6,298,000 after buying an additional 26,009 shares during the last quarter. Seven Eight Capital LP increased its stake in Arrowhead Pharmaceuticals by 592.3% during the first quarter. Seven Eight Capital LP now owns 75,224 shares of the biotechnology company’s stock valued at $2,151,000 after purchasing an additional 64,358 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Arrowhead Pharmaceuticals by 21.2% in the first quarter. Swiss National Bank now owns 243,300 shares of the biotechnology company’s stock valued at $6,958,000 after buying an additional 42,600 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.